2022
DOI: 10.1038/s41380-022-01476-z
|View full text |Cite|
|
Sign up to set email alerts
|

Differential expression of MicroRNAs in Alzheimer’s disease: a systematic review and meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
28
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(29 citation statements)
references
References 41 publications
1
28
0
Order By: Relevance
“…A recent meta-analysis [ 101 ] highlighted the difficulties encountered when studying miRNAs in AD patients. Of about 1500 miRNAs extracted from different biological matrices (blood, CFS, MCI, and the brain), 56 miRNAs showing significant differential expression in AD compared with the healthy controls and 10 novel miRNAs were found in the blood, and 2 of them were downregulated: miR-103, which is involved in neurite transportation, and miR-107, which is involved in BACE1 regulation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A recent meta-analysis [ 101 ] highlighted the difficulties encountered when studying miRNAs in AD patients. Of about 1500 miRNAs extracted from different biological matrices (blood, CFS, MCI, and the brain), 56 miRNAs showing significant differential expression in AD compared with the healthy controls and 10 novel miRNAs were found in the blood, and 2 of them were downregulated: miR-103, which is involved in neurite transportation, and miR-107, which is involved in BACE1 regulation.…”
Section: Discussionmentioning
confidence: 99%
“…A recent meta-analysis showed that 40 miRNAs were significantly upregulated and 16 were downregulated in AD versus healthy controls. The analysis revealed that they were mainly involved in pathways related to apoptosis, immune response, and inflammation [ 101 ].…”
Section: Microrna and Cu Metabolism In Disease Statesmentioning
confidence: 99%
“…AD places a tremendous socioeconomic burden on caregivers and on the healthcare system as a whole. Despite ~115 years of intense and directed research, no effective treatment or cure for AD exists, although many insights into the molecular-genetic nature of this age-related disease have been established (Alzheimer et al, 1995 ; Kaur et al, 2015 ; Lane et al, 2018 ; Dong et al, 2021 ; Hermans et al, 2021 ; Trejo-Lopez et al, 2021 ; Liu et al, 2022 ; Olufunmilayo and Holsinger, 2022 ; Pogue et al, 2022 ; Rastegar-Moghaddam et al, 2022 ; Singh et al, 2022 ; Tahami Monfared et al, 2022 ; Yoon et al, 2022 ). As a devastating, inflammatory, and terminal neurodegenerative disorder, one molecular genetic component that has emerged at the forefront of current AD research is the DNA-binding element NF-kB, probably the single most important transcription factor yet identified in the complex neuropathology of AD.…”
Section: Alzheimer's Disease (Ad): Epidemiology and Basic Featuresmentioning
confidence: 99%
“…Exposure to these factors induces IkB decomposition triggered through a site-specific phosphorylation of an IκB kinase (IKK) complex, followed by degradation via the ubiquitin-proteasome system, and then rapid NF-kB-activated transcription by multiple pro-inflammatory NF-kB-sensitive gene promoters. The human brain and CNS contain a very active, pleiotropic NF-kB-signaling system that has a function in both neurological health and disease (Kaltschmidt and Kaltschmidt, 2009 ; Christian et al, 2016 ; Liu et al, 2022 ; Yoon et al, 2022 ). While the NF-kB (p50/p65; also known as p50/RelA) heterodimer is especially abundant in nervous tissues, other homo- or hetero-dimeric NF-kB transcription factor complexes containing at least 5 other molecular components that include RelA, RelB, c-Rel, p50, p52, and NFKB1 (p105) form at least 12 different identified NF-kB complexes.…”
Section: Nf-κb-sensitive Micrornas and Inflammatory Signaling In Alzh...mentioning
confidence: 99%
See 1 more Smart Citation